Christian Schem, MD

Articles by Christian Schem, MD

116 Impact of Neoadjuvant Chemotherapy (NACT) Response on Clinical Outcomes With Ribociclib (RIB) in HR+/HER2− EBC: A Subgroup Analysis From the Phase 3 NATALEE Trial

ByNicholas McAndrew,Stephen Chia,Fabio Puglisi,Yann Izarzugaza,Christian Schem, MD,Binghe Xu,Fanny Le Du,Priyanka Sharma, MD,Peter A. Fasching,Alejandro Rodriguez,Murat Akdere,Yogesh Chattar,Juan Pablo Zarate,Aditya Bardia, MD, MPH, FASCO

May 13th 2026

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

BySara A. Hurvitz, MD,Michal Jarzab,Montserrat Munoz Mateu,Erin Cobain,Jin Zhang,Arielle Medford,Alistair Ring,Priyanka Sharma, MD,Christian Schem, MD,Ionut Temciuc,Zheng Li,Juan Pablo Zarate,Denise A. Yardley, MD

June 26th 2025

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

ByNicholas McAndrew,Stephen Chia,Fabio Puglisi,Aditya Bardia, MD, MPH, FASCO,Yann Izarzugaza,Christian Schem, MD,Binghe Xu,Fanny Le Du,Priyanka Sharma, MD,Karen Afenjar,Murat Akdere,Juan Pablo Zarate,Yogesh Chattar,Peter A. Fasching

June 23rd 2025

Expanding Role of Ovarian Suppression/ Ablation in Premenopausal ER-Positive Breast Cancer: Issues and Opportunities

ByChristian Schem, MD,Walter Jonat, MD

January 2nd 2009

Luteinizing hormone-releasing hormone analogs (LHRHa) are often used alone or in combination with tamoxifen to suppress ovarian function in premenopausal women with endocrine-responsive breast cancer. However, aromatase inhitiors (AIs) are now the preferred first-line endocrine treatment for postmenopausal women with breast cancer.

Christian Schem, MD

Articles by Christian Schem, MD

116 Impact of Neoadjuvant Chemotherapy (NACT) Response on Clinical Outcomes With Ribociclib (RIB) in HR+/HER2− EBC: A Subgroup Analysis From the Phase 3 NATALEE Trial

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Expanding Role of Ovarian Suppression/ Ablation in Premenopausal ER-Positive Breast Cancer: Issues and Opportunities

Latest Updated Articles

Trending on CancerNetwork

Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML

BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC

MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

Training, Invasiveness, and Workload Behind Falling Prostate Brachytherapy Use

Young Adults With Lung Cancer Often Fall Outside Screening Guidelines